A comprehensive approach to tobacco dependence interventions

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 4, 2015, Pages 481-488

  Baldassarri, Stephen R ^a   Toll, Benjamin A ^a,b,c   Leone, Frank T ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Addiction; Cessation; Chronic obstructive pulmonary disease (COPD); Cigarette; Nicotine; Smoking; Tobacco

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; SHORT ACTING DRUG; VARENICLINE;

ANGER; ANXIETY; COUNSELING; DEPRESSION; ELECTRONIC CIGARETTE; FOOD AND DRUG ADMINISTRATION; FRUSTRATION; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MULTICENTER STUDY (TOPIC); NICOTINE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SADNESS; SLEEP DISORDER; SMOKING; SMOKING CESSATION; SNUS; TOBACCO; TOBACCO DEPENDENCE; WEIGHT GAIN; WITHDRAWAL SYNDROME; CHRONIC DISEASE; TOBACCO USE DISORDER;

CHRONIC DISEASE; HUMANS; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84943330625     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.04.007     Document Type: Article

References (84)

1. Office on Smoking and Health; National Center for Chronic Disease Prevention and Health Promotion. Reports of the Surgeon General. In: The health consequences of smokinge50 years of progress: a report of the Surgeon General. Atlanta (Ga): Centers for Disease Control and Prevention; 2014.
2. Fiore MC, Schroeder SA, Baker TB. Smoke, the chief killerestrategies for targeting combustible tobacco use. N Engl J Med 2014;370:297-9.
3. Smoking-attributable mortality, years of potential life lost, and productivity lossese United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008;57:1226-8.
4. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, et al. Smoking and mortality-beyond established causes. N Engl J Med 2015;372:631-40.
5. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381-90.
6. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9.
7. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9.
8. Connett JE, Kusek JW, Bailey WC, O'Hara P, Wu M. Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. Control Clin Trials 1993;14:3S-19S.
9. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002;57:967-72.
10. Jimenez-Ruiz CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001;119:1365-70.
11. Benowitz NL. Nicotine addiction. N Engl J Med 2010;362:2295-303.
12. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993;33:23-9.
13. Fowler JS, Logan J, Wang GJ, Volkow ND. Monoamine oxidase and cigarette smoking. Neurotoxicology 2003;24:75-82.
14. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. Neurotoxicology 2007;28:182-95.
15. Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev 2005;48:420-37.
16. Govind AP, Vezina P, Green WN. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol 2009;78:756-65.
17. Hughes JR, Gulliver SB, Fenwick JW, Valliere WA, Cruser K, Pepper S, et al. Smoking cessation among self-quitters. Health Psychol 1992;11:331-4.
18. Garvey AJ, Bliss RE, Hitchcock JL, Heinold JW, Rosner B. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav 1992;17:367-77.
19. Ward KD, Klesges RC, Zbikowski SM, Bliss RE, Garvey AJ. Gender differences in the outcome of an unaided smoking cessation attempt. Addict Behav 1997;22:521-33.
20. Norregaard J, Tonnesen P, Petersen L. Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med 1993;22:261-71.
21. Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 1997;5:137-42.
22. A clinical practice guideline for treating tobacco use and dependence:2008 update. A U.S. Public Health Service report. Am J Prev Med 2008;35:158-76.
23. Russell MA, Wilson C, Taylor C, Baker CD. Effect of general practitioners' advice against smoking. BMJ 1979;2:231-5.
24. Fiore MC, Jorenby DE, Schensky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. Mayo Clin Proc 1995;70:209-13.
25. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol 2005;1:91-111.
26. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010 Jan 20;(1)CD006936.
27. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol 2004;72:371-81.
28. Fiore MC, Baker TB. Clinical practice. Treating smokers in the health care setting. N Engl J Med 2011;365:1222-31.
29. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598-600.
30. Morris JF, Temple W. Spirometric "lung age" estimation for motivating smoking cessation. Prev Med 1985;14:655-62.
31. Bize R, Burnand B, Mueller Y, Rege-Walther M, Camain JY, Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2012;12:Cd004705.
32. Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav 2011;36:764-8.
33. Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess 2008;12:1-135. iii-iv, ix-xi.
34. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024.
35. Cheong Y, Yong HH, Borland R. Does how you quit affect success? A comparison between abrupt and gradual methods using data from the International Tobacco Control Policy Evaluation Study. Nicotine Tob Res 2007;9:801-10.
36. Lindson-Hawley N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012;11: Cd008033.
37. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 2015;313:687-94.
38. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 2003;98:1395-402.
39. Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. Addiction 2005;100:1074-89.
40. Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. Arch Intern Med 2011;171:1901-7.
41. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
42. Baker TB, Piper ME, McCarthy DE, Bolt DM, Smith SS, Kim SY, et al. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res 2007;9:S555-70.
43. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 1992;60:689-97.
44. Toll BA, O'Malley SS, McKee SA, Salovey P, Krishnan-Sarin S. Confirmatory factor analysis of the Minnesota Nicotine Withdrawal Scale. Psychol Addict Behav 2007;21:216-25.
45. West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 1989;19:981-5.
46. Bars MP, Banauch GI, Appel D, Andreachi M, Mouren P, Kelly KJ, et al. "Tobacco Free With FDNY": the New York City Fire Department World Trade Center Tobacco Cessation Study. Chest 2006;129:979-87.
47. Sachs DP. Tobacco dependence treatment: time to change the paradigm. Chest 2006;129:836-9.
48. Steinberg MB, Foulds J, Richardson DL, Burke MV, Shah P. Pharmacotherapy and smoking cessation at a tobacco dependence clinic. Prev Med 2006;42:114-9.
49. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:Cd006103.
50. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012;11:Cd000146.
51. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA 2014;311:193-4.
52. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005 Apr 18;(2):CD001292.
53. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008;53:1217-22.
54. Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, et al. "Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res 2014;20:301-9.
55. Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. Nicotine Tob Res 2013;15:348-54.
56. Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 2015;175:504-11.
57. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010;152:144-51.
58. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Arch Intern Med 1994;154:989-95.
59. Meine TJ, Patel MR, Washam JB, Pappas PA, Jollis JG. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005;95:976-8.
60. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007;131:446-52.
61. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008;359:2018-24.
62. Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793-801.
63. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71.
64. Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2015;265:259-68.
65. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013;2:Cd007253.
66. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010;33:289-301.
67. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007 Jan 24;(1):CD000031.
68. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;5:Cd009329.
69. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009;66:1253-62.
70. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014;312:155-61.
71. Chan SS, Leung DY, Abdullah AS, Wong VT, Hedley AJ, Lam TH. A randomized controlled trial of a smoking reduction plus nicotine replacement therapy intervention for smokers not willing to quit smoking. Addiction 2011;106:1155-63.
72. Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 2006;8:739-49.
73. Fairchild AL, Bayer R, Colgrove J. The renormalization of smoking? E-cigarettes and the tobacco "endgame". N Engl J Med 2014;370:293-5.
74. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014;23:133-9.
75. Drummond MB, Upson D. Electronic cigarettes: potential harms and benefits. Ann Am Thorac Soc 2014;11:236-42.
76. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One 2013;8:e66317.
77. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013;382:1629-37.
78. Kaufman AR, Mays D, Koblitz AR, Portnoy DB. Judgments, awareness, and the use of snus among adults in the United States. Nicotine Tob Res 2014;16:1404-8.
79. Lund KE, Scheffels J, McNeill A. The association between use of snus and quit rates for smoking: results from seven Norwegian cross-sectional studies. Addiction 2011;106:162-7.
80. Ramstrom LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tob Control 2006;15:210-4.
81. Foulds J, Ramstrom L, Burke M, Fagerström K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tobacco Control 2003;12:349-59.
82. Schildt EB, Eriksson M, Hardell L, Magnuson A. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int J Cancer 1998;77:341-6.
83. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Institute of Medicine Committee to Assess the Science Base for Tobacco Harm Reduction, Board on Health Promotion and Disease Prevention. Clearing the smoke: assessing the science base for tobacco harm reduction. Washington (DC): National Academies Press; 2001.
84. Fagerstrom K, Rutqvist LE, Hughes JR. Snus as a smoking cessation aid: a randomized placebo-controlled trial. Nicotine Tob Res 2012;14:306-12.